<DOC>
	<DOCNO>NCT02652624</DOCNO>
	<brief_summary>This study evaluate efficacy switch fixed-dose combination ( FDC ) bictegravir/emtricitabine/tenofovir alafenamide ( B/F/TAF ) versus continue regimen consist elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide ( E/C/F/TAF ) , elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate ( E/C/F/TDF ) , atazanavir ( ATV ) + ritonavir ( RTV ) + emtricitabine/tenofovir disoproxil fumarate ( FTC/TDF ) virologically suppress HIV-1 infected woman .</brief_summary>
	<brief_title>Safety Efficacy Switching FDC B/F/TAF From E/C/F/TAF , E/C/F/TDF , ATV+RTV+FTC/TDF Virologically Suppressed HIV-1 Infected Women</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Key Inclusion Criteria Medically stable HIV1 infect woman meet follow criterion : Completion Week 48 openlabel extension ( OLE ) visit post Week 48 OLE visit Gileadsponsored study GS US 236 0128 , Completion Week 96 visit post Week 96 visit Gileadsponsored study GS US2920109 completion Week 144 visit post Week 144 visit Gilead sponsor study GSUS2920104 GSUS2920111 . Currently stable antiretroviral regimen consist E/C/F/TAF , E/C/F/TDF , ATV+RTV+FTC/TDF continuously ≥ 12 consecutive week precede screen visit Documented plasma HIV1 RNA level &lt; 50 copies/mL ≥ 12 week precede Screening visit . After reach HIV1 RNA &lt; 50 copies/mL , single value HIV1 RNA ≥ 50 copies/mL follow resuppression &lt; 50 copies/mL allow HIV1 RNA &lt; 50 copies/mL screening Estimated glomerular filtration rate ( eGFR ) ≥ 50 mL/min ( ≥ 0.83 mL/sec ) accord CockcroftGault formula screen visit Note : Other Protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>